TNFRSF9 and neoplasm: Furthermore, immunohistochemical staining for CD3 in tumor sections revealed a 1.28‐ and 1.32‐fold increase in CD3+ T cells in the anti‐4‐1BB‐treated (p < 0.05) and TST‐treated (p < 0.05) tumors, respectively (Figure 8D), compared to the control group.